Biotech's very bad start to the year continues as microcap gene therapy player Sio ditches CEO, lead partnership
In a biotech market hit from top to bottom by dwindling investor sentiment, small firms, in particular, are bearing the brunt of the burden. Now, a tiny gene therapy player is rethinking its direction and cutting away a key partnership to make ends meet.
Sio Gene Therapies has elevated CFO David Nassif into the interim CEO role as it says goodbye to current helmsman Pavan Cheruvu, who has left the company to “pursue new opportunities,” the biotech said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,300+ biopharma pros reading Endpoints daily — and it's free.